Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,824.66
(
0.62%
)
US TECH 100
24,378.40
(
0.56%
)
Dow Jones
48,185.80
(
0.58%
)
Brent Oil
94.49
(
0.04%
)
Bitcoin
72,224.00
(
0.61%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: biopharm post# 271214

Tuesday, 11/08/2016 5:20:08 PM

Tuesday, November 08, 2016 5:20:08 PM

Post# of 347009
Janssen/Johnson Johnson closing in with Dmitry Gabrilovich and realize how important PS Targeting truly is.... heck, I believe JnJ/Janssen have known for quite some time how big PS Targeting would become.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote